Skip to main
QURE
QURE logo

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 29 analyst ratings
Buy
Strong Buy 41%
Buy 45%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV reported revenues of $27.1M for 2024, marking a significant 71% year-over-year increase, largely attributed to $10M in license revenue from HEMGENIX royalties and $11M in collaboration revenue with Bristol Myers Squibb. The probability of success for its AMT-130 gene therapy has been raised to 75%, with expectations for a commercial launch in 2026, bolstered by promising FDA feedback and a supportive endpoint in clinical trials. Additionally, the risk-adjusted revenue estimates have increased to $1.8B, reflecting enhanced confidence in AMT-130's potential to become a breakthrough treatment for Huntington's disease.

Bears say

The financial outlook for uniQure NV appears negative due to decreased revenue estimates, with projections now suggesting annual peak revenues exceeding $2 billion may be difficult to achieve. Significant reductions in research and development expenses, resulting from a 65% workforce cut and facility sales, could impact the company's ability to advance its clinical pipeline effectively. Additionally, numerous risks, including potential delays in commercial launches and regulatory uncertainties, contribute to the speculative nature of uniQure's stock, indicating substantial volatility and uncertainties surrounding its future revenues.

uniQure (QURE) has been analyzed by 29 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 45% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 29 analysts, uniQure (QURE) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.